Poolbeg Pharma secures first national patent for cancer immunotherapy side-effect treatment

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has reached a significant milestone in its intellectual property strategy after Australia granted the first national patent in its programme targeting a serious side effect of cancer immunotherapy. IP Australia, the Australian patent office, has granted protection covering the use of any p38 MAPK inhibitor.